drug · small molecule

ARBLI

updated 3mo ago

by $SCNX Scienture Holdings, Inc.🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 8

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 7 approved and 6 investigational indications.

targets

Type-1 angiotensin II receptor

all catalysts(0)

nothing on the calendar yet

Trials studying ARBLI

phase1Losartan Potassium/Hydrochlorothiazide 100/25 mg Tablets in Healthy Subjects Under Non-Fasting Conditionscompletedn=80
phase4Losartan and HCTZ and Amlodipine vs Atenolol and Amlodipine (0954A-309)(COMPLETED)completedn=120
phase4ALLOGRAFT, A Study to Evaluate the Renal Protective Effects of Losartan (0954-222)(COMPLETED)completedn=367
phase3Evaluate the Safety and Anti-Hypertensive Efficacy of Hyzaar(R) In Patients With Mild To Moderate Essential Hypertension (0954A-323)completedn=62
phase4Hydrochlorothiazide (+) Losartan Potassium vs. Amlodipine Comparative Study (0954A-314)completedn=174
phase3HYZAAR vs. Ramipril for Diabetes (0954A-245)(COMPLETED)completedn=312
phase3An Open Label Study to Assess the Efficacy, Safety and Tolerability of COZAAR Plus (Losartan Potassium 50mg/Hydrochlorothiazide 12.5mg) Possibly Titrated up to COZAAR Plus-F (Losartan Potassium 100mg/Hydrochlorothiazide 25mg) in Patients With Essential Hypertension (0954A-325)terminatedn=11
phase3MK0954A-264 Filter Study (0954A-264)(COMPLETED)completedn=274

more trials →

News(0)

no news has mentioned this drug yet

brand

ARBLI

trade names

Cozaar, Losaprex, Losartan potassium, Losartan potassium component of hyzaar

generic

LOSARTAN POTASSIUM

MOA

12.1 Mechanism of Action Angiotensin II [formed from angiotensin I in a reaction catalyzed by angiotensin converting enzyme (ACE, kininase II)] is a potent vasoconstrictor, the primary vasoactive hormone of the renin-angiotensin system, and an important component in the pathophysiology of hypertension. It also stimulates aldosterone secretion by the adrenal cortex. Losartan and its principal active metabolite block the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT 1 receptor found in many tissues, (e.g., vascular smooth muscle, adrenal gland). There is also an AT 2 receptor found in many tissues, but it is not known to be associated with cardiovascular homeostasis. Neither losartan nor its principal active metabolite exhibits any partial agonist activity at the AT 1 receptor, and both have much greater affinity (about 1,000-fold) for the AT 1 receptor than for the AT 2 receptor. In vitro binding studies indicate that losartan is a reversible, competitive inhibitor of the AT 1 receptor. The active metabolite is 10 to 40 times more potent by weight than losartan and appears to be a reversible, noncompetitive inhibitor of the AT 1 receptor. Neither losartan nor its active metabolite inhibits ACE (kininase II, the enzyme that converts angiotensin I to angiotensin II and degrades bradykinin), nor do they bind to or block other hormone receptors or ion channels known to be important in cardiovascular regulation.

indication

1 INDICATIONS AND USAGE Arbli is an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy. There is evidence that this benefit does not apply to Black patients. ( 1.2 ) Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension. ( 1.3 ) 1.1 Hypertension Arbli is indicated for the treatment of hypertension in adults and pediatric patients 6 years of age and older, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and nonfatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely re

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 2m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug · small molecule

save

ARBLI

updated 3mo ago

by $SCNX Scienture Holdings, Inc.🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 8

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 7 approved and 6 investigational indications.

targets

Type-1 angiotensin II receptor

all catalysts(0)

nothing on the calendar yet

Trials studying ARBLI

phase1Losartan Potassium/Hydrochlorothiazide 100/25 mg Tablets in Healthy Subjects Under Non-Fasting Conditionscompletedn=80
phase4Losartan and HCTZ and Amlodipine vs Atenolol and Amlodipine (0954A-309)(COMPLETED)completedn=120
phase4ALLOGRAFT, A Study to Evaluate the Renal Protective Effects of Losartan (0954-222)(COMPLETED)completedn=367
phase3Evaluate the Safety and Anti-Hypertensive Efficacy of Hyzaar(R) In Patients With Mild To Moderate Essential Hypertension (0954A-323)completedn=62
phase4Hydrochlorothiazide (+) Losartan Potassium vs. Amlodipine Comparative Study (0954A-314)completedn=174
phase3HYZAAR vs. Ramipril for Diabetes (0954A-245)(COMPLETED)completedn=312
phase3An Open Label Study to Assess the Efficacy, Safety and Tolerability of COZAAR Plus (Losartan Potassium 50mg/Hydrochlorothiazide 12.5mg) Possibly Titrated up to COZAAR Plus-F (Losartan Potassium 100mg/Hydrochlorothiazide 25mg) in Patients With Essential Hypertension (0954A-325)terminatedn=11
phase3MK0954A-264 Filter Study (0954A-264)(COMPLETED)completedn=274

more trials →

News(0)

no news has mentioned this drug yet

brand

ARBLI

trade names

Cozaar, Losaprex, Losartan potassium, Losartan potassium component of hyzaar

generic

LOSARTAN POTASSIUM

MOA

indication

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 2m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

ARBLI

🐶 often sniffed alongside

targets

all catalysts(0)

Trials studying ARBLI

News(0)

Report a data issue

comments(0)

ARBLI

🐶 often sniffed alongside

targets

all catalysts(0)

Trials studying ARBLI

News(0)

Report a data issue

comments(0)